• Profile
Close

Cost-effectiveness and comparative effectiveness of biologic therapy for asthma

Annals of Allergy, Asthma, and Immunology Mar 15, 2019

Anderson WC, et al. - Researchers assessed the cost-efficacy and comparative effectiveness of FDA-approved biologics for the treatment of asthma by analyzing relevant studies and documents published 2016-2019. Upon analysis, they found current pricing for all biologics exceeded measures of cost-effectiveness. A minimum reduction of ~60% in prices would be required in order to meet available measures indicating cost-effectiveness. Identification of predictors of response among those receiving oral corticosteroid therapy and evaluation of the influence of treatment for decisions that relate to continuation are the key aspects that should be emphasized to maximize cost-effectiveness of the biologics, according to the investigators. Responsible application of biologic therapy may be ensured with multidisciplinary stakeholder efforts.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay